Abstract
DOC monotherapy is an optional Japanese standard of care for chemo-naïve elderly patients (pts) with advanced NSCLC. DOC+RAM showed superior survival benefit over DOC in second-line for NSCLC. A Japanese phase II study comparing DOC+RAM and DOC showed febrile neutropenia (FN) incidence of one-third in DOC+RAM. DOC+RAM could be a promising candidate for elderly NSCLC pts, but such high FN incidence is a critical concern. We thus adopted a routine primary prophylactic PEG-G-CSF to reduce FN and maximize the efficacy of DOC+RAM in elderly pts.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
